ERBB2 and gastric cancer: The anti‐HER2 antibody, trastuzumab, has proven to be an effective targeted therapy, showing significant efficacy in the treatment of HER2‐positive breast cancer,46 gastric cancer,47 and gastroesophageal (GE) junction adenocarcinoma.48